Sensei Biotherapeutics, Inc., an immuno-oncology company, announced the submission of an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for a phase 1/2 clinical trial of SNS-101, a conditionally active VISTA-blocking antibody, in patients with solid tumours.
SNS-101 is a conditionally active, human monoclonal IgG1 antibody designed to selectively block the VISTA checkpoint in the tumour microenvironment, which acts as a suppressor of T cells by binding the receptor PSGL-1. Preclinical studies have demonstrated SNS-101
